Changzheng Xinkai’s Ainuohua Gets SFDA Approval For Treating Lupus Nephritis
This article was originally published in PharmAsia News
Executive Summary
Suzhou Changzheng Xinkai Pharmaceutical has received China's State FDA approval for its Ainuohua (leflunomide tablets), representing the first drug for the treatment of lupus nephritis to be launched in China. In 2000, Changzheng Xinkai applied to expand the drug's indication for adult rheumatic arthritis to lupus nephritis. In 2002, Peking University First Hospital and nine other authoritative healthcare institutions launched a five-year multicenter, controlled clinical trial. The trial results show that Ainuohua achieved an overall response rate of 80 percent in relieving lupus nephritis, effectively reduced 24-hour urine protein and Systemic Lupus Erythematosus Disease Activity Index score, and increased serum albumin and complement level. Particularly noteworthy is the drug's safety and ability to reverse some patients' renal pathological changes. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.